-
1.发明授权Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV) 失效作为二肽基肽酶-IV（DDP-IV）抑制剂的药物组合物公开(公告)号：US08637546B2
公开(公告)日：2014-01-28
申请号：US13437999
申请日：2012-04-03
Applicant: David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
Inventor： David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
IPC: A61K31/445 , C07D295/00
CPC classification number: C07D207/27 , C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12
Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，X综合征，高胰岛素血症，肥胖，动脉粥样硬化和各种免疫调节疾病 。
-
公开(公告)号：US20110263599A1
公开(公告)日：2011-10-27
申请号：US13088206
申请日：2011-04-15
Applicant: Xiaohong Song , Hong Ding , Steven W. Elmore , Milan Bruncko , David J. Madar , Andrew J. Souers , Cheol-Min Park , Zhi-Fu Tao , Xilu Wang , Aaron R. Kunzer
Inventor： Xiaohong Song , Hong Ding , Steven W. Elmore , Milan Bruncko , David J. Madar , Andrew J. Souers , Cheol-Min Park , Zhi-Fu Tao , Xilu Wang , Aaron R. Kunzer
IPC: A61K31/404 , C07D401/10 , A61K31/454 , C07D413/10 , A61K31/5377 , A61P35/00 , C07D403/04 , A61K31/4155 , C07D413/06 , C07D403/06 , A61K31/496 , C07D209/42 , A61K31/4439
CPC classification number: C07D209/42 , C07D403/04
Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.
Abstract translation: 公开了抑制抗凋亡Mcl-1蛋白活性的化合物，含有该化合物的组合物，以及治疗涉及过表达或未调节的Mcl-1蛋白的疾病的方法。
-
公开(公告)号：US20090054426A1
公开(公告)日：2009-02-26
申请号：US12195937
申请日：2008-08-21
Applicant: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
Inventor： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC: A61K31/496 , A61P25/00 , A61K31/5375 , A61K31/445 , A61K31/16
CPC classification number: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
Abstract translation: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法，包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年性痴呆，艾滋病痴呆，神经变性，抑郁和精神分裂症，包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
4.发明申请公开(公告)号：US20080312214A1
公开(公告)日：2008-12-18
申请号：US12197760
申请日：2008-08-25
Applicant: Vince S. Yeh , Ravi Kurukulasuriya , David J. Madar , James T. Link
Inventor： Vince S. Yeh , Ravi Kurukulasuriya , David J. Madar , James T. Link
IPC: A61K31/55 , A61K31/4439 , A61K31/4015 , A61P25/22 , A61P25/24 , A61P25/28
CPC classification number: C07D401/14 , C07D207/26 , C07D207/267 , C07D401/12 , C07D403/12
Abstract: Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 用于治疗患有糖皮质激素相关疾病和病症的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂，其中所述抑制剂是式（I）的化合物： 或其药学上可接受的盐，前药，前药的盐或其组合。 抑制11-β-羟基类固醇脱氢酶1型酶的方法。 治疗由过度糖皮质激素作用介导的神经元变性，功能障碍，急性精神病，焦虑，痴呆，抑郁症，非胰岛素依赖型2型糖尿病，胰岛素抵抗，肥胖症，脂质疾病，代谢综合征和其他疾病和病症的方法。
-
5.发明授权Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) 失效药物组合物作为二肽基肽酶-IV（DPP-IV）的抑制剂公开(公告)号：US07238724B2
公开(公告)日：2007-07-03
申请号：US11036258
申请日：2005-01-13
Applicant: David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
Inventor： David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
IPC: A61K31/40 , A61K31/401 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D405/12 , C07D401/12 , C07D211/58 , C07D239/42
CPC classification number: C07D207/16 , C07D207/27 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12
Abstract: The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）并可用于预防或治疗糖尿病，特别是II型糖尿病以及高血糖症，X综合症，高胰岛素血症，肥胖症，动脉粥样硬化和各种免疫调节疾病的化合物 。
-
Patent Agency Ranking
公开(公告)号：US08940902B2
公开(公告)日：2015-01-27
申请号：US13554698
申请日：2012-07-20
Applicant: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
Inventor： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC: C07D211/74 , A61K31/44 , A61K31/495
CPC classification number: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
Abstract translation: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法，包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年性痴呆，艾滋病痴呆，神经退行性疾病，抑郁症和精神分裂症，包括向需要这种治疗的患者施用有效量的11-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
7.发明授权公开(公告)号：US07737137B2
公开(公告)日：2010-06-15
申请号：US12197760
申请日：2008-08-25
Applicant: Michael E. Brune , Peer B. Jacobson , Jeffrey J. Rohde , Jiahong Wang , Steven Fung , Ravi Kurukulasuriya , David J. Madar , James T. Link , Vince S. Yeh
Inventor： Michael E. Brune , Peer B. Jacobson , Jeffrey J. Rohde , Jiahong Wang , Steven Fung , Ravi Kurukulasuriya , David J. Madar , James T. Link , Vince S. Yeh
CPC classification number: C07D401/14 , C07D207/26 , C07D207/267 , C07D401/12 , C07D403/12
Abstract: Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 用于治疗患有糖皮质激素相关疾病和病症的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂，其中所述抑制剂是式（I）的化合物： 或其药学上可接受的盐，前药，前药的盐或其组合。 抑制11-β-羟基类固醇脱氢酶1型酶的方法。 治疗由过度糖皮质激素作用介导的神经元变性，功能障碍，急性精神病，焦虑，痴呆，抑郁症，非胰岛素依赖型2型糖尿病，胰岛素抵抗，肥胖症，脂质疾病，代谢综合征和其他疾病和病症的方法。
-
公开(公告)号：US08445679B2
公开(公告)日：2013-05-21
申请号：US12104294
申请日：2008-04-16
Applicant: Xilu Wang , Xiaohong Song , Steven W. Elmore , Milan Bruncko , David J. Madar , Andrew J. Souers , Lisa A. Hasvold , Le Wang , Zhi-Fu Tao , Aaron K. Kunzer
Inventor： Xilu Wang , Xiaohong Song , Steven W. Elmore , Milan Bruncko , David J. Madar , Andrew J. Souers , Lisa A. Hasvold , Le Wang , Zhi-Fu Tao , Aaron K. Kunzer
IPC: C07D403/04 , A61K31/497
CPC classification number: C07D209/42 , A61K31/5377 , C07D209/34 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D491/113
Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.
Abstract translation: 公开了抑制抗凋亡Mcl-1蛋白活性的化合物，含有该化合物的组合物，以及治疗涉及过表达或未调节的Mcl-1蛋白的疾病的方法。
-
9.发明授权Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) 失效药物组合物作为二肽基肽酶-IV（DPP-IV）的抑制剂公开(公告)号：US08119664B2
公开(公告)日：2012-02-21
申请号：US12727558
申请日：2010-03-19
Applicant: David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
Inventor： David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
IPC: A61K31/445 , C07D295/00
CPC classification number: C07D207/27 , C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12
Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，X综合征，高胰岛素血症，肥胖，动脉粥样硬化和各种免疫调节疾病 。
-
10.发明申请Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) 失效药物组合物作为二肽基肽酶-IV（DPP-IV）的抑制剂公开(公告)号：US20100190822A1
公开(公告)日：2010-07-29
申请号：US12727558
申请日：2010-03-19
Applicant: David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
Inventor： David J. Madar , Stevan W. Djuric , Melissa J. Michmerhuizen , Hana A. Kopecka , Xiaofeng Li , Kenton L. Longenecker , Zhonghua Pei , Daisy Pireh , Hing L. Sham , Kent D. Stewart , Bruce G. Szczepankiewicz , Paul E. Wiedeman , Hong Yong
IPC: A61K31/4725 , C07D207/16 , A61K31/40 , A61P3/10 , A61P3/04 , A61P3/08 , C07D401/08 , C07D401/14 , A61K31/4545 , C07D401/12 , A61K31/454 , A61K31/4439 , C07D403/08 , A61K31/4025
CPC classification number: C07D207/27 , C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12
Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，X综合征，高胰岛素血症，肥胖，动脉粥样硬化和各种免疫调节疾病 。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.03 seconds)
